Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01432444 · ClinicalTrials.gov registry record · Phase 3
Open-label Study to Compare Hospitalization Rates of Schizophrenic Patients Treated With Oral Antipsychotics Versus IM Depot Aripiprazole
A Phase 3 study, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- Completed
- Registry status
- Phase 3
- Development phase
- 493
- Enrollment target
NCT01432444 is a Phase 3 study that has completed, run by Otsuka Pharmaceutical Development & Commercialization. The registered enrollment target is 493 participants.
The verdict
NCT01432444, a Phase 3 study, has completed, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 493 participants
- Enrollment target
Study Summary
The purpose of this study is to compare retrospective hospitalization rates of schizophrenic patients treated with oral antipsychotics to prospective hospitalization rates of these patients treated with IM depot aripiprazole.
Interventions
- DRUG Aripiprazole (Abilify®) IM Depot Injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 493 participants |
| Start Date | 2011-09 |
| Est. Completion | 2013-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01432444
The ClinicalTrials.gov registry entry for NCT01432444 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 493 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Otsuka Pharmaceutical Development & Commercialization, which has 221 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Aripiprazole (Abilify®) IM Depot Injection is the first listed.
NCT01432444 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01432444 about?
NCT01432444 is a clinical study titled "Open-label Study to Compare Hospitalization Rates of Schizophrenic Patients Treated With Oral Antipsychotics Versus IM Depot Aripiprazole". The purpose of this study is to compare retrospective hospitalization rates of schizophrenic patients treated with oral antipsychotics to prospective hospitalization rates of these patients treated with IM depot aripiprazole.
What is the current status of trial NCT01432444?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 493 participants. The study started on 2011-09. Estimated completion is 2013-12.
What interventions are being tested in trial NCT01432444?
The interventions under investigation include: Aripiprazole (Abilify®) IM Depot Injection (DRUG).
Who is sponsoring clinical trial NCT01432444?
This trial is sponsored by Otsuka Pharmaceutical Development & Commercialization, which has 221 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.